Document is current
Any future updates will be listed below
-
Authors
Zheng, Yuqi
Alzoubi, Islam
Graeber, Manuel B.
Anand, Atul https://orcid.org/0000-0001-7474-5433
Barazzuol, Lara
Dorostkar, Mario
Frontzek, Karl
Golebiewska, Anna https://orcid.org/0000-0002-4160-2521
Hadjipanayis, Costas G.
Hortobagyi, Tibor
Ismail, Azzam
Jansen, Gerard H.
Kaminska, Bozena
Kirschenbaum, Daniel
Komohara, Yoshihiro
Kristensen, Bjarne Winther https://orcid.org/0000-0002-6352-0826
Lee, Kevin S.
Le Rhun, Emilie https://orcid.org/0000-0002-9408-3278
Lu, Q. Richard
Matiasek, Kaspar
Mawrin, Christian
Michelucci, Alessandro https://orcid.org/0000-0003-1230-061X
Montemurro, Nicola
Mouthon, Marc-André
Liu, Quan
Reimann, Regina
Sankowski, Roman https://orcid.org/0000-0001-9215-8021
Schcolnik-Cabrera, Alejandro https://orcid.org/0000-0001-7734-3253
Schulz, Michael https://orcid.org/0000-0001-6731-9188
Schürch, Christian M. https://orcid.org/0000-0002-1792-1768
Schwabenland, Marius
Tchoghandjian, Aurélie
Valiulytė-Simaitė, Indrė
Viapiano, Mariano S. https://orcid.org/0000-0002-8756-388X
Weiss, Tobias
Weller, Michael https://orcid.org/0000-0002-1748-174X
Wintermark, Max
-
Funding
Funding for this research was provided by:
The University of Sydney
- License Information
-
More Information
Article History
Received: 2 December 2025
Revised: 14 February 2026
Accepted: 9 March 2026
First Online: 16 April 2026
Declarations
:
: ELR has received a research grants from BMS, Servier and honoraria for lectures or advisory board participation or consulting Bayer, Biodexa, Janssen, Leo Pharma, Pfizer, Pierre Fabre, Seagen and Servier. MW has received research grants from Lundbeck and Novartis, and honoraria for lectures or advisory board participation or consulting from Curevac, Hemerion, Iqvia, Medac, Novartis, Novocure, Orbus, Philogen and Servier.
